### Tables

1.1 Classification of 153 Canadian studies from 2001 to 2006 15  
1.2 Costs and effects for alternative gallstone treatments 18  
1.3 Cost and effect per patient for worksite care and regular care 19  
1.4 Detection rates for successive stool guaiac tests 22  
1.5 Bednet usage in Kenya in the Millennium Village and in the MV region 25  
1.6 Evaluation of neo-natal intensive care treatment 26  
2.1 Short run production function for lengths of stay 35  
2.2 Short run cost curves for lengths of stay 35  
2.3 Long run production function for lengths of stay 36  
2.4 Discount factors for alternative time horizons and interest rates 38  
2.5 Avoidable costs in SEK of liver cirrhosis for women compared to base year, ten years 39  
2.6 Reference requirements for five treatments (per 100 bed-days) 45  
2.7 Costs and cost-effectiveness ($C/E$) for three live kidney donor transplant treatments 46  
2.8 Inflation-controlled hospital costs for total knee arthroplasty 48  
2.9 Total costs and cost profiles of 17 prevention interventions targeting CSWs in Tamil Nadu and Andhra Pradesh in India in 2002–03 51  
2.10 Lifetime costs of HIV 54  
2.11 Costs of different treatments before and after treatment 56  
2.12 Costs of liver cirrhosis for women compared to base year, 24 years 58  
3.1 Percentage of cases where RCC-estimated costs are within 10 percent of RVU-estimated costs 70  
3.2 DATCAP costs from 110 substance abuse treatment programs 72  
3.3 Estimates of economies of scope for Danish hospitals 74  
3.4 DRGs that give different profitability outcomes using RVUs and RCCs 76  
3.5 Resource based relative values and Medicare charges 78  
3.6 Estimates of the share of the physician’s bill that counts as costs 81  
3.7 DATCAP costs for 302 clients and 440 client episodes 82  
3.8 Human resource cost per chest X-ray films 84  
3.9 Hypothetical translation of a patient’s bill: charges to costs 85  
3.10 Hypothetical use of cost centers 85  
4.1 Consequences of increased taxes in consumer surplus loss to drinkers and lives saved 102  
4.2 Literature estimates of costs and benefits on a comparable basis 105  
4.3 Comparison of optimal and actual policies for schistomiasis 109  
4.4 Effect of education of household members on health care outcomes (change in probabilities) 111
8.7 NICE decisions ranked by ICER with their associated probability of rejection 236
8.8 Balance sheet of expected effect of demonstration program on number of people covered, services covered and financial costs 238
8.9 Cost-effectiveness ratio estimates of THA and other procedures 242
9.1 Utility values using TTO for patients versus general public by duration 248
9.2 Mean time trade-off and visual analogue scores 250
9.3 Intra-class correlation using time trade-off 251
9.4 The Rosser and Kind index of health status 254
9.5 Valuation of EuroQol health states 261
9.6 Annual transition probabilities for monotherapy 264
9.7 Calculation of life expectancy over 20 cycles for monotherapy for the case study Markov model 265
9.8 Selected results from comparative valuation studies 267
9.9 Mean SG, TTO and RS quality weights for health state E 268
9.10 The seven health profiles included in the experiment 269
9.11 Implied rankings of the seven health profiles for different quality weights 269
9.12 Mean Spearman rank correlation coefficients between the direct rankings and the predicted rankings of RS, TTO and SG 270
9.13 Results for visual function and utility values according to visual acuity 271
9.14 Patients willing to trade time for improved vision (TTO method) and risk immediate death for improved vision (SG method) 272
9.15 Ratings of standardized health states 273
9.16 HUI Mark 2 classification scheme 275
9.17 Change in health state utility after hearing aid fitting and ICER 276
9.18 Coefficient estimates and significance levels of the determinants of HIV/AIDS utilities 278
10.1 Revised disability classes for the Global Burden Disease Study based on the results of the PTO protocol used at the Geneva meeting on disability weights 287
10.2 DALY losses by age at death in Uganda 288
10.3 Comparison of DALYs versus deaths in demographically developing countries by categories of disease 288
10.4 Global disability adjusted life years 1990 to 2010 289
10.5 Life expectancies at birth and after intervention (remaining years) 289
10.6 Utilities for health states with knee condition 293
10.7 The ICECAP-O instrument, attributes and values 298
10.8 The number of lives, life years and QALYs saved among 50-year-olds and 70-year-olds equivalent to saving one life, life year and QALY among 30-year-olds 302
10.9 Incremental cost-effectiveness analysis for sleeping sickness in Uganda 303
10.10 Apparent impact of HIV on mortality: DALYs as compared with HealYs, 1990 305
10.11 Comparison of restrained and non-restrained clients 306
10.12 Correlations between ICECAP-O, well-being indices and EuroQoL 308
11.1 The value of a quality adjusted life year (1997 dollars) by study type 323
11.2 WTP per QALY for each health state 324
11.3 WTP per QALY in six countries 325
11.4 Costs and benefits of alternative mental health programs 326
11.5 Age-group specific VSLs 331
11.6 Comparison of the VSLs using the cross-sections with that of the cohort analysis 331
11.7 Costs and benefits of the 55 mph speed limit decision using different numeraires 335
11.8 Summary of Clear Skies initiative benefits based on EPA VSLs versus VSLs estimated by Aldy and Viscusi 337
12.1 Estimated value of waiting list time 354
12.2 Monetary valuations of NHS nursing home care and hospital care for respondents with a preference for NHS nursing home care 364
12.3 Conjoint analysis results for the choice of medication versus surgery for the management of miscarriage 366
12.4 The costs and benefits of mobile screening in NSW 369
13.1 Price elasticities for health in Peru by income quintile 381
13.2 Weighted net benefits of case management programs with alternative sets of distribution weights 391
13.3 Number responding and stated willingness to pay as percentage of family income 392
13.4 Equivalence numbers in questionnaires without and with explicit arguments 393
13.5 Numbers weights for severity of illness corresponding to PTO estimates 394
13.6 Aggregate results: percentage change in total demand accounted for by each income quintile and consumers’ welfare loss as a percentage of income by income quintile 395
13.7 Disaggregated results for quantity reductions \( \frac{D}{D} \) by quintile 396
13.8 Disaggregated results for benefit losses as a percentage of income \( \frac{B}{Y} \) by quintile 397
13.9 Disaggregated costs and benefits of raising user fees in Peru by quintile 402
13.10 The weight for each of the three social objectives behind public hospital construction decisions in Turkey 403
14.1 HIV/AIDS by region, December 2012 412
14.2 Costs of MC interventions relative to treating infections not averted due to MC 417
14.3 Cost–benefit outcomes for VCT options 432
14.4 Net benefits per person of ARVs on depressed and non-depressed groups by era 437
14.5 WTP for an HIV/AIDS vaccine according to income 439